Willow Biosciences Inc. announced a collaboration with a leading Active Pharmaceutical Ingredient manufacturer to develop a more sustainable, cost-effective manufacturing route for their largest product sold globally. Willow's collaboration partner, who currently holds a significant world market share of the API market, recognized the need to employ more sustainable methods to manufacture its APIs with reduced cost and less waste and sought Willow's expertise in developing and scaling a manufacturing process for this key ingredient. The new partnership program will focus on optimization of an existing commercial biomanufacturing process for improved performance at scale.

The development phase of this funded collaboration is expected to last approximately six months with additional milestone payments to be made for achieving defined performance targets. This agreement represents the second new development agreement executed by Willow in only the first few weeks of 2024, with a robust pipeline of other potential collaborations in process.